Drug Trial Radar · NCT07672574
Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Agomab Spain S.L.U.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open, two-part study in healthy male volunteers, aged 30-65 years. This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of radiolabelled test medicine (\[14C\]ontunisertib) and determine the routes and rates of elimination of the test medicine.
Conditions
- Fibrostenotic Crohn's Disease
Interventions
OntunisertibDrug
Oral capsule
[14C]ontunisertibDrug
IV infusion
[14C]ontunisertibDrug
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute bioavailability of ontunisertib following oral and IV administrationTime frame: Through study completion, an average of 8 days
- Cumulative amount of total radioactivity excreted in urine and fecesTime frame: Through study completion, an average of 10 days
- Chemical structure of each metabolite accounting for ≥10% of circulating total radioactivity and Metabolite profiling accounting for >80% of total radioactivity recovered in urine and/or fecesTime frame: Through study completion, an average of 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences Limited
Nottingham, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.